Houston-based Milkify will pitch their freeze-drying breast milk concept on Shark Tank this Friday. Photo courtesy of Milkify

A Houston startup is competing in the "Super Bowl of Business," as founder Pedro Silva calls it, and you can watch the action later this week.

Milkify will appear on ABC’s “Shark Tank” this Friday, April 7. Silva, co-founder and CEO, created Milkify along with his wife, Berkley Luck, PhD, in 2019. Today, Luck is a mom, COO, and a molecular biologist, but she had the idea for the company back in grad school. A coworker was struggling with pumping breast milk “lugging the pump back to work,” as Luck puts it.

Luck was studying probiotics at the time and was using a freeze-dryer in her work. The problem inspired her to create a process of freeze-drying breast milk that is now patent pending. The trademarked process is centered around SafeDry, special freeze-drying pouches.

“The breast milk never makes contact with our equipment,” Luck explains. The powdered milk is transferred directly from the bag in which it’s freeze-dried to the final packaging under sterile conditions. The result is not only shelf-stable, but keeps for at least three years, exponentially longer than frozen milk.

Silva admits that when Luck first pitched Milkify to him, he thought it was a crazy idea. “But Berkley is way smarter than I am. There must be something to it,” he realized. At the time, he was working in energy private equity. But he vowed that if they could find a viable path to making Milkify a business, he would join Luck full-time.

Early in the company’s life, the couple purchased a blue van that said “We will freeze-dry your breast milk,” recalls Silva. This grassroots marketing introduced them to a neighbor whose baby refused to drink her frozen milk. “He spat it out, he hated the taste,” Silva says. The pair freeze-dried her milk for the baby and their neighbor soon sent a video of the little one chugging six ounces of her rehydrated milk.

“That was the lightbulb moment,” says Silva. “How often do you get to work on something really meaningful?”

Since its founding, Milkify has freeze-dried and powdered more than half a million ounces of breast milk, all carefully preserved and packaged individually. Last October, Milkify opened what Luck claims is, “The only GMP-certified processing facility in the world right now specifically designed for freeze-drying breast milk.”

The 6,400-square-foot Houston space is a vast improvement from the previous 200-square-foot facility. That was thanks to raising $1.2 million in funds, which has also allowed them to build a larger staff.

“Our entire workforce at this point other than Pedro is moms,” says Luck. Including the couple, they are a team of 10, and just hired two additional members. They are currently looking to hire, says Silva, with roles including both operations and logistics associates. Experience, he says, is less important than conscientiousness and a good attitude, as they will train their new hires in-house.

And Milkify is about to receive more attention than ever with its appearance on “Shark Tank.” “Getting on a national stage to share our story was the main motivation for it,” says Luck. That translates to both education about the potential for freeze-drying breast milk, and about Milkify’s unique model.

“We started this business as a labor of love. It wasn’t just a financial reason,” says Silva. “This can actually help a lot of people. This is a way to spread the word.” And in the process, help countless moms and babies.

Berkley Luck and Pedro Silva — the wife and husband team behind Milkify — appear on Shark Tank this Friday. Photo courtesy of Milkify

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston doctor wins NIH grant to test virtual reality for ICU delirium

Virtual healing

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal.

While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU).

The five-year study will focus on older patients using mental stimulation techniques to reduce incidences of delirium. The award comes courtesy of the National Institute on Aging K76 Paul B. Beeson Emerging Leaders Career Development Award in Aging.

“As the population of older adults continues to grow, the need for effective, scalable interventions to prevent postoperative complications like delirium is more important than ever,” Faisal said in a news release.

ICU delirium is a serious condition that can lead to major complications and even death. Roughly 87 percent of patients who undergo major surgery involving intubation will experience some form of delirium coming out of anesthesia. Causes can range from infection to drug reactions. While many cases are mild, prolonged ICU delirium may prevent a patient from following medical advice or even cause them to hurt themselves.

Using VR games to treat delirium is a rapidly emerging and exciting branch of medicine. Studies show that VR games can help promote mental activity, memory and cognitive function. However, the full benefits are currently unknown as studies have been hampered by small patient populations.

Faisal believes that half of all ICU delirium cases are preventable through VR treatment. Currently, a general lack of knowledge and resources has been holding back the advancement of the treatment.

Hopefully, the work of Faisal in one of the busiest medical cities in the world can alleviate that problem as she spends the next half-decade plugging patients into games to aid in their healing.

Houston scientists develop breakthrough AI-driven process to design, decode genetic circuits

biotech breakthrough

Researchers at Rice University have developed an innovative process that uses artificial intelligence to better understand complex genetic circuits.

A study, published in the journal Nature, shows how the new technique, known as “Combining Long- and Short-range Sequencing to Investigate Genetic Complexity,” or CLASSIC, can generate and test millions of DNA designs at the same time, which, according to Rice.

The work was led by Rice’s Caleb Bashor, deputy director for the Rice Synthetic Biology Institute and member of the Ken Kennedy Institute. Bashor has been working with Kshitij Rai and Ronan O’Connell, co-first authors on the study, on the CLASSIC for over four years, according to a news release.

“Our work is the first demonstration that you can use AI for designing these circuits,” Bashor said in the release.

Genetic circuits program cells to perform specific functions. Finding the circuit that matches a desired function or performance "can be like looking for a needle in a haystack," Bashor explained. This work looked to find a solution to this long-standing challenge in synthetic biology.

First, the team developed a library of proof-of-concept genetic circuits. It then pooled the circuits and inserted them into human cells. Next, they used long-read and short-read DNA sequencing to create "a master map" that linked each circuit to how it performed.

The data was then used to train AI and machine learning models to analyze circuits and make accurate predictions for how untested circuits might perform.

“We end up with measurements for a lot of the possible designs but not all of them, and that is where building the (machine learning) model comes in,” O’Connell explained in the release. “We use the data to train a model that can understand this landscape and predict things we were not able to generate data on.”

Ultimately, the researchers believe the circuit characterization and AI-driven understanding can speed up synthetic biology, lead to faster development of biotechnology and potentially support more cell-based therapy breakthroughs by shedding new light on how gene circuits behave, according to Rice.

“We think AI/ML-driven design is the future of synthetic biology,” Bashor added in the release. “As we collect more data using CLASSIC, we can train more complex models to make predictions for how to design even more sophisticated and useful cellular biotechnology.”

The team at Rice also worked with Pankaj Mehta’s group in the department of physics at Boston University and Todd Treangen’s group in Rice’s computer science department. Research was supported by the National Institutes of Health, Office of Naval Research, the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the American Heart Association, National Library of Medicine, the National Science Foundation, Rice’s Ken Kennedy Institute and the Rice Institute of Synthetic Biology.

James Collins, a biomedical engineer at MIT who helped establish synthetic biology as a field, added that CLASSIC is a new, defining milestone.

“Twenty-five years ago, those early circuits showed that we could program living cells, but they were built one at a time, each requiring months of tuning,” said Collins, who was one of the inventors of the toggle switch. “Bashor and colleagues have now delivered a transformative leap: CLASSIC brings high-throughput engineering to gene circuit design, allowing exploration of combinatorial spaces that were previously out of reach. Their platform doesn’t just accelerate the design-build-test-learn cycle; it redefines its scale, marking a new era of data-driven synthetic biology.”